# Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

> **NCT00100932** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 106 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** E7389 28 Day Cycle
- **DRUG:** E7389 21 Day Cycle

## Key facts

- **NCT ID:** NCT00100932
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2012-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100932, "Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00100932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*